Allergic rhinitis (AR) is a chronic inflammatory disease of nasal mucosa involved in a variety of signal pathways and cytokines. Toll-like receptors (TLRs), an important pattern recognition receptor (PRRs), mediate intracellular signal transduction pathways, participate in the innate and adaptive immune responses, and play an important role in the initiation and progression of AR. Recently, TLRs as therapeutic targets have achieved good efficacy in the treatment of AR, and TLRs agonists can be used as immunological agents or immunological adjuvants, which have a promising future in the immunotherapy of AR. To further develop the possible value of TLRs agonists in the clinic, this article summarizes the research progress of TLRs agonists in the treatment of allergic rhinitis.